Skip to main content

This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.

Publisher: Bentham Science Publishers

Volume 11, Number 1, March 2011

Articles

Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
pp. 1-7(7)
Authors: Loizzo, S.; Capasso, A.; L. Loizzo, A.; Spampinato, S.; Campana, G.; Di Giannuario, A.; Pieretti, S.; Loizzo, A.

Favourites:
ADD
Favourites:
ADD

The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
pp. 23-31(9)
Authors: Das, Arghya; Mukhopadhyay, Sangita

Favourites:
ADD

Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
pp. 32-53(22)
Authors: Ahmed Khan, Nisar; Benner, Robbert

Favourites:
ADD

TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
pp. 54-67(14)
Authors: Santoni, Giorgio; Farfariello, Valerio

Favourites:
ADD

Application of Innate Immune Molecules for a New Class of Drugs: Infection, Inflammation and Beyond
pp. 68-75(8)
Authors: J. Kimura, H.; Suzuki, K.; A. Landek-Salgado, M.; Caturegli, P.; Jounai, N.; Kobiyama, K.; Takeshita, F.

Favourites:
ADD
Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more